Phase II study of procarbazine, CCNU, and vincristine combination chemotherapy in the treatment of malignant brain tumors. Academic Article uri icon

Overview

abstract

  • Forty-eight patients with primary or metastatic malignant tumors of the central nervous system (CNS) were treated with combination chemotherapy, consisting or procarbazine (100 mg/m2 X 14 days), CCNU (75 mg/m2), and vincristine (1.4 mg/m2 X 2, 1 week apart) (PCV) every 4 weeks. Most patients had undergone initial resection of primary tumors, postoperative radiotherapy, and a post irradiation interval of 3 months or more. Other patients harbored unbiopsied, newly-discovered primary or metastatic tumors. All patients were deteriorating neurologically when treatment began. Overall response rate for PCV combination therapy was 44%, no better than results obtained with single agent procarbazine or BCNU, the most effective drugs used alone in previous brain tumor chemotherapy studies.

publication date

  • May 1, 1975

Research

keywords

  • Brain Neoplasms
  • Lomustine
  • Nitrosourea Compounds
  • Procarbazine
  • Vincristine

Identity

Scopus Document Identifier

  • 0016799866

Digital Object Identifier (DOI)

  • 10.1002/1097-0142(197505)35:5<1398::aid-cncr2820350524>3.0.co;2-c

PubMed ID

  • 1122488

Additional Document Info

volume

  • 35

issue

  • 5